Company intelligence / Profile preview

Cloverleaf Bio

New Haven, Connecticut, United Statescloverleafbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Cloverleaf Bio has developed a novel platform using engineered transfer RNA (tRNA) molecules designed to directly inhibit multiple enzymes required for cancer cell growth. The company’s approach allows a single therapeutic molecule to target up to 25 different enzymes. As of April 2024, the company appears to be in early/preclinical development and has received support from the biotech community but has not yet reported clinical results

Therapeutic areas: Oncology
Modalities: engineered tRNA therapeuticsRNA therapeutics
Industry: Biotech

Beyond the preview

Go deeper on Cloverleaf Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cloverleaf Bio.

Explore the full profile